In vitro mycobacterial growth inhibition assays: A tool for the assessment of protective immunity and evaluation of tuberculosis vaccine efficacy

Vaccine

Volumn 34, Issue 39, 2016, Pages 4656-4665

  Tanner, Rachel ^a   O'Shea, Matthew K ^a   Fletcher, Helen A ^b   McShane, Helen ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Immunity; MGIA; Mycobacterial growth inhibition assay; Tuberculosis; Vaccine

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH DIFFERENTIATION FACTOR 15; INTERLEUKIN 12; INTERLEUKIN 21; INTERLEUKIN 27; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ASSAY; BACTERIAL IMMUNITY; BCG VACCINATION; BLOOD; BONE MARROW DERIVED MACROPHAGE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE RESPONSE; DRUG EFFICACY; HUMAN; HUMORAL IMMUNITY; INNATE IMMUNITY; MACROPHAGE; MYCOBACTERIAL GROWTH INHIBITION ASSAY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SPLEEN CELL; T LYMPHOCYTE SUBPOPULATION; TUBERCULOSIS; ANIMAL; GROWTH, DEVELOPMENT AND AGING; MICROBIOLOGICAL EXAMINATION; MYCOBACTERIUM TUBERCULOSIS; PROCEDURES;

ANIMALS; BACTERIOLOGICAL TECHNIQUES; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84991585039     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.07.058     Document Type: Review

References (99)

1. [1] Thakur, A., Pedersen, L.E., Jungersen, G., Immune markers and correlates of protection for vaccine induced immune responses. Vaccine 30 (2012), 4907–4920.
2. [2] Orme, I.M., Miller, E.S., Roberts, A.D., Furney, S.K., Griffin, J.P., Dobos, K.M., et al. T lymphocytes mediating protection and cellular cytolysis during the course of Mycobacterium tuberculosis infection. Evidence for different kinetics and recognition of a wide spectrum of protein antigens. J Immunol 148 (1992), 189–196.
3. [3] Flynn, J.L., Chan, J., Triebold, K.J., Dalton, D.K., Stewart, T.A., Bloom, B.R., An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178 (1993), 2249–2254.
4. [4] Cooper, A.M., Dalton, D.K., Stewart, T.A., Griffin, J.P., Russell, D.G., Orme, I.M., Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 178 (1993), 2243–2247.
5. [5] Bustamante, J., Boisson-Dupuis, S., Abel, L., Casanova, J.L., Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-γ immunity. Semin Immunol 26 (2014), 454–470.
6. [6] Mattila, J.T., Diedrich, C.R., Lin, P.L., Phuah, J., Flynn, J.L., Simian immunodeficiency virus-induced changes in T cell cytokine responses in cynomolgus macaques with latent Mycobacterium tuberculosis infection are associated with timing of reactivation. J Immunol 186 (2011), 3527–3537.
7. [7] Lazarevic, V., Nolt, D., Flynn, J.L., Long-term control of Mycobacterium tuberculosis infection is mediated by dynamic immune responses. J Immunol 175 (2005), 1107–1117.
8. [8] Mittrücker, H.W., Steinhoff, U., Köhler, A., Krause, M., Lazar, D., Mex, P., et al. Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis. Proc Natl Acad Sci USA 104 (2007), 12434–12439.
9. [9] Elias, D., Akuffo, H., Britton, S., PPD induced in vitro interferon gamma production is not a reliable correlate of protection against Mycobacterium tuberculosis. Trans R Soc Trop Med Hyg 99 (2005), 363–368.
10. [10] Boaz, M.J., Waters, A., Murad, S., Easterbrook, P.J., Vyakarnam, A., Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection. J Immunol 169 (2002), 6376–6385.
11. [11] Darrah, P.A., Patel, D.T., De Luca, P.M., Lindsay, R.W., Davey, D.F., Flynn, B.J., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13 (2007), 843–850.
12. [12] Kagina, B.M., Abel, B., Scriba, T.J., Hughes, E.J., Keyser, A., Soares, A., et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. Am J Respir Crit Care Med 182 (2010), 1073–1079.
13. [13] Fletcher, H.A., Snowden, M.A., Landry, B., Rida, W., Satti, I., Harris, S.A., et al. T-cell activation is an immune correlate of risk in BCG vaccinated infants. Nat Commun, 7, 2016, 11290.
14. [14] https://www.nc3rs.org.uk/the-3rs [accessed 2016].
15. [15] Youmans, G.P., Mechanisms of immunity in tuberculosis. Pathobiol Annu 9 (1979), 137–162.
16. [16] Crowle, A.J., May, M., Preliminary demonstration of human tuberculoimmunity in vitro. Infect Immun 31 (1981), 453–464.
17. [17] Crowle, A.J., Ross, E.J., May, M.H., Inhibition by 1,25(OH)2-vitamin D3 of the multiplication of virulent tubercle bacilli in cultured human macrophages. Infect Immun 55 (1987), 2945–2950.
18. [18] Rook, G.A., Steele, J., Fraher, L., Barker, S., Karmali, R., O'Riordan, J., et al. Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology 57 (1986), 159–163.
19. [19] Steele, J., Flint, K.C., Pozniak, A.L., Hudspith, B., Johnson, M.M., Rook, G.A., Inhibition of virulent Mycobacterium tuberculosis by murine peritoneal macrophages and human alveolar lavage cells: the effects of lymphokines and recombinant gamma interferon. Tubercle 67 (1986), 289–294.
20. [20] Cheng, S.H., Walker, L., Poole, J., Aber, V.R., Walker, K.B., Mitchison, D.A., et al. Demonstration of increased anti-mycobacterial activity in peripheral blood monocytes after BCG vaccination in British school children. Clin Exp Immunol 74 (1988), 20–25.
21. [21] Sutherland, I., Springett, V.H., Effectiveness of BCG vaccination in England and Wales in 1983. Tubercle 68 (1987), 81–92.
22. [22] Cheng, S.H., Walker, K.B., Lowrie, D.B., Mitchison, D.A., Swamy, R., Datta, M., et al. Monocyte antimycobacterial activity before and after Mycobacterium bovis BCG vaccination in Chingleput, India, and London, United Kingdom. Infect Immun 61 (1993), 4501–4503.
23. [23] Tripathy, S.P., Fifteen-year follow-up of the Indian BCG prevention trial. Proceedings of the 26th world conference of the international union against tuberculosis, Singapore, 1986, 69–72.
24. [24] Silver, R.F., Li, Q., Boom, W.H., Ellner, J.J., Lymphocyte-dependent inhibition of growth of virulent Mycobacterium tuberculosis H37Rv within human monocytes: requirement for CD4+ T cells in purified protein derivative-positive, but not in purified protein derivative-negative subjects. J Immunol 160 (1998), 2408–2417.
25. [25] Houk, V.N., Baker, J.H., Sorensen, K., Kent, D.C., The epidemiology of tuberculosis infection in a closed environment. Arch Environ Health 16 (1968), 26–35.
26. [26] Hoft, D.F., Worku, S., Kampmann, B., Whalen, C.C., Ellner, J.J., Hirsch, C.S., et al. Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity. J Infect Dis 186 (2002), 1448–1457.
27. [27] Worku, S., Hoft, D.F., In vitro measurement of protective mycobacterial immunity: antigen-specific expansion of T cells capable of inhibiting intracellular growth of bacille Calmette-Guérin. Clin Infect Dis 30:Suppl. 3 (2000), S257–S261.
28. [28] Worku, S., Hoft, D.F., Differential effects of control and antigen-specific T cells on intracellular mycobacterial growth. Infect Immun 71 (2003), 1763–1773.
29. [29] Kampmann, B., Gaora, P.O., Snewin, V.A., Gares, M.P., Young, D.B., Levin, M., Evaluation of human antimycobacterial immunity using recombinant reporter mycobacteria. J Infect Dis 182 (2000), 895–901.
30. [30] Newton, S., Martineau, A., Kampmann, B., A functional whole blood assay to measure viability of mycobacteria, using reporter-gene tagged BCG or M.Tb (BCGlux/M.Tb lux). J Vis Exp, 2011.
31. [31] Burl, S., Holder, B.S., Lo, B.K., Kampmann, B., Optimisation of a functional mycobacterial growth-inhibition assay to improve its suitability for infant TB vaccine studies. J Immunol Methods 394 (2013), 121–124.
32. [32] Kampmann, B., Tena, G.N., Mzazi, S., Eley, B., Young, D.B., Levin, M., Novel human in vitro system for evaluating antimycobacterial vaccines. Infect Immun 72 (2004), 6401–6407.
33. [33] Tena, G.N., Young, D.B., Eley, B., Henderson, H., Nicol, M.P., Levin, M., et al. Failure to control growth of mycobacteria in blood from children infected with human immunodeficiency virus and its relationship to T cell function. J Infect Dis 187 (2003), 1544–1551.
34. [34] Wallis, R.S., Palaci, M., Vinhas, S., Hise, A.G., Ribeiro, F.C., Landen, K., et al. A whole blood bactericidal assay for tuberculosis. J Infect Dis 183 (2001), 1300–1303.
35. [35] Wallis, R.S., Vinhas, S.A., Johnson, J.L., Ribeiro, F.C., Palaci, M., Peres, R.L., et al. Whole blood bactericidal activity during treatment of pulmonary tuberculosis. J Infect Dis 187 (2003), 270–278.
36. [36] Wallis, R.S., Vinhas, S., Janulionis, E., Strain specificity of antimycobacterial immunity in whole blood culture after cure of tuberculosis. Tuberculosis (Edinb) 89 (2009), 221–224.
37. [37] Janulionis, E., Sofer, C., Schwander, S.K., Nevels, D., Kreiswirth, B., Shashkina, E., et al. Survival and replication of clinical Mycobacterium tuberculosis isolates in the context of human innate immunity. Infect Immun 73 (2005), 2595–2601.
38. [38] Cheon, S.H., Kampmann, B., Hise, A.G., Phillips, M., Song, H.Y., Landen, K., et al. Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosis. Clin Diagn Lab Immunol 9 (2002), 901–907.
39. [39] Fletcher, H.A., Tanner, R., Wallis, R.S., Meyer, J., Manjaly, Z.R., Harris, S., et al. Inhibition of mycobacterial growth in vitro following primary but not secondary vaccination with Mycobacterium bovis BCG. Clin Vaccine Immunol 20 (2013), 1683–1689.
40. [40] Tala-Heikkila, M., Nurmela, T., Tala, E., Tuominen, J., Evaluation of the BCG revaccination programme of schoolchildren in Finland. Bull Int Union Tuberc Lung Dis 66 (1991), 57–59.
41. [41] Leung, C.C., Tam, C.M., Chan, S.L., Chan-Yeung, M., Chan, C.K., Chang, K.C., Efficacy of the BCG revaccination programme in a cohort given BCG vaccination at birth in Hong Kong. Int J Tuberc Lung Dis 5 (2001), 717–723.
42. [42] Sepulveda, R.L., Parcha, C., Sorensen, R.U., Case-control study of the efficacy of BCG immunization against pulmonary tuberculosis in young adults in Santiago, Chile. Tuber Lung Dis 73 (1992), 372–377.
43. [43] Rodrigues, L.C., Pereira, S.M., Cunha, S.S., Genser, B., Ichihara, M.Y., de Brito, S.C., et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 366 (2005), 1290–1295.
44. [44] Fine, P.E., Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346 (1995), 1339–1345.
45. [45] Harris, S.A., Meyer, J., Satti, I., Marsay, L., Poulton, I.D., Tanner, R., et al. Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination. J Infect Dis 209 (2014), 1259–1268.
46. [46] Cowley, S.C., Elkins, K.L., CD4+ T cells mediate IFN-gamma-independent control of Mycobacterium tuberculosis infection both in vitro and in vivo. J Immunol 171 (2003), 4689–4699.
47. [47] Parra, M., Yang, A.L., Lim, J., Kolibab, K., Derrick, S., Cadieux, N., et al. Development of a murine mycobacterial growth inhibition assay for evaluating vaccines against Mycobacterium tuberculosis. Clin Vaccine Immunol 16 (2009), 1025–1032.
48. [48] Sada-Ovalle, I., Chiba, A., Gonzales, A., Brenner, M.B., Behar, S.M., Innate invariant NKT cells recognize Mycobacterium tuberculosis-infected macrophages, produce interferon-gamma, and kill intracellular bacteria. PLoS Pathog, 4, 2008, e1000239.
49. [49] Marsay, L., Matsumiya, M., Tanner, R., Poyntz, H., Griffiths, K.L., Stylianou, E., et al. Mycobacterial growth inhibition in murine splenocytes as a surrogate for protection against Mycobacterium tuberculosis (M.tb). Tuberculosis (Edinb) 93 (2013), 551–557.
50. [50] Carpenter, E., Fray, L., Gormley, E., Cellular responses and Mycobacterium bovis BCG growth inhibition by bovine lymphocytes. Immunol Cell Biol 75 (1997), 554–560.
51. [51] Denis, M., Wedlock, D.N., Buddle, B.M., Ability of T cell subsets and their soluble mediators to modulate the replication of Mycobacterium bovis in bovine macrophages. Cell Immunol 232 (2004), 1–8.
52. [52] Kolibab, K., Parra, M., Yang, A.L., Perera, L.P., Derrick, S.C., Morris, S.L., A practical in vitro growth inhibition assay for the evaluation of TB vaccines. Vaccine 28 (2009), 317–322.
53. [53] Zelmer, A., Tanner, R., Stylianou, E., Morris, S., Izzo, A., Williams, A., et al. Ex vivo mycobacterial growth inhibition assay (MGIA) for tuberculosis vaccine testing – a protocol for mouse splenocytes. BioRxiv, 2015.
54. [54] Boom, W.H., Gammadelta T cells and Mycobacterium tuberculosis. Microbes Infect 1 (1999), 187–195.
55. [55] Hoft, D.F., Brown, R.M., Roodman, S.T., Bacille Calmette-Guérin vaccination enhances human gamma delta T cell responsiveness to mycobacteria suggestive of a memory-like phenotype. J Immunol 161 (1998), 1045–1054.
56. [56] Spencer, C.T., Abate, G., Sakala, I.G., Xia, M., Truscott, S.M., Eickhoff, C.S., et al. Granzyme A produced by γ(9)δ(2) T cells induces human macrophages to inhibit growth of an intracellular pathogen. PLoS Pathog, 9, 2013, e1003119.
57. [57] Liu, J., Tran, V., Leung, A.S., Alexander, D.C., Zhu, B., BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy. Hum Vaccin 5 (2009), 70–78.
58. [58] Orme, I.M., The Achilles heel of BCG. Tuberculosis (Edinb) 90 (2010), 329–332.
59. [59] Kaveh, D.A., Carmen Garcia-Pelayo, M., Hogarth, P.J., Persistent BCG bacilli perpetuate CD4 T effector memory and optimal protection against tuberculosis. Vaccine 32 (2014), 6911–6918.
60. [60] Kamath, A., Woodworth, J.S., Behar, S.M., Antigen-specific CD8+ T cells and the development of central memory during Mycobacterium tuberculosis infection. J Immunol 177 (2006), 6361–6369.
61. [61] Stenger, S., Rosat, J.P., Bloom, B.R., Krensky, A.M., Modlin, R.L., Granulysin: a lethal weapon of cytolytic T cells. Immunol Today 20 (1999), 390–394.
62. [62] Chan, J., Xing, Y., Magliozzo, R.S., Bloom, B.R., Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med 175 (1992), 1111–1122.
63. [63] MacMicking, J.D., North, R.J., LaCourse, R., Mudgett, J.S., Shah, S.K., Nathan, C.F., Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci USA 94 (1997), 5243–5248.
64. [64] Vordermeier, H.M., Villarreal-Ramos, B., Cockle, P.J., McAulay, M., Rhodes, S.G., Thacker, T., et al. Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect Immun 77 (2009), 3364–3373.
65. [65] Rook, G.A., Steele, J., Ainsworth, M., Champion, B.R., Activation of macrophages to inhibit proliferation of Mycobacterium tuberculosis: comparison of the effects of recombinant gamma-interferon on human monocytes and murine peritoneal macrophages. Immunology 59 (1986), 333–338.
66. [66] Douvas, G.S., Looker, D.L., Vatter, A.E., Crowle, A.J., Gamma interferon activates human macrophages to become tumoricidal and leishmanicidal but enhances replication of macrophage-associated mycobacteria. Infect Immun 50 (1985), 1–8.
67. [67] Rojas, M., Barrera, L.F., Puzo, G., Garcia, L.F., Differential induction of apoptosis by virulent Mycobacterium tuberculosis in resistant and susceptible murine macrophages: role of nitric oxide and mycobacterial products. J Immunol 159 (1997), 1352–1361.
68. [68] Chan, E.D., Chan, J., Schluger, N.W., What is the role of nitric oxide in murine and human host defense against tuberculosis? Current knowledge. Am J Respir Cell Mol Biol 25 (2001), 606–612.
69. [69] Achkar, J.M., Chan, J., Casadevall, A., B cells and antibodies in the defense against Mycobacterium tuberculosis infection. Immunol Rev 264 (2015), 167–181.
70. [70] Turneer, M., Van Vooren, J.P., Nyabenda, J., Legros, F., Lecomte, A., Thiriaux, J., et al. The humoral immune response after BCG vaccination in humans: consequences for the serodiagnosis of tuberculosis. Eur Respir J 1 (1988), 589–593.
71. [71] Lagercrantz, R., Enell, H., Tuberculin-sensitivity and antibodies (agglutinins) after BCG-vaccination. Acta Paediatr 42 (1953), 316–322.
72. [72] Beyazova, U., Rota, S., Cevheroğlu, C., Karsligil, T., Humoral immune response in infants after BCG vaccination. Tuber Lung Dis 76 (1995), 248–253.
73. [73] Hoft, D.F., Kemp, E.B., Marinaro, M., Cruz, O., Kiyono, H., McGhee, J.R., et al. A double-blind, placebo-controlled study of Mycobacterium-specific human immune responses induced by intradermal bacille Calmette-Guérin vaccination. J Lab Clin Med 134 (1999), 244–252.
74. [74] Krambovitis, E., Detection of antibodies to Mycobacterium tuberculosis plasma membrane antigen by enzyme-linked immunosorbent assay. J Med Microbiol 21 (1986), 257–264.
75. [75] Kardjito, T., Handoyo, I., Grange, J.M., Diagnosis of active tuberculosis by immunological methods. 1. The effect of tuberculin reactivity and previous BCG vaccination on the antibody levels determined by ELISA. Tubercle 63 (1982), 269–274.
76. [76] de Vallière, S., Abate, G., Blazevic, A., Heuertz, R.M., Hoft, D.F., Enhancement of innate and cell-mediated immunity by antimycobacterial antibodies. Infect Immun 73 (2005), 6711–6720.
77. [77] Chen, T., Blanc, C., Eder, A.Z., Prados-Rosales, R., Souza, A.C., Kim, R.S., et al. Association of human antibodies to arabinomannan with enhanced mycobacterial opsonophagocytosis and intracellular growth reduction. J Infect Dis, 2016.
78. [78] Naranbhai, V., Fletcher, H., Tanner, R., O'Shea, M., McShane, H., Fairfax, B., et al. Distinct transcriptional and anti-mycobacterial profiles of peripheral blood monocytes dependent on the ratio of monocytes: lymphocytes. EBioMedicine 2 (2015), 1619–1626.
79. [79] Denis, M., Buddle, B.M., Bovine dendritic cells are more permissive for Mycobacterium bovis replication than macrophages, but release more IL-12 and induce better immune T-cell proliferation. Immunol Cell Biol 86 (2008), 185–191.
80. [80] Henderson, R.A., Watkins, S.C., Flynn, J.L., Activation of human dendritic cells following infection with Mycobacterium tuberculosis. J Immunol 159 (1997), 635–643.
81. [81] Tailleux, L., Neyrolles, O., Honoré-Bouakline, S., Perret, E., Sanchez, F., Abastado, J.P., et al. Constrained intracellular survival of Mycobacterium tuberculosis in human dendritic cells. J Immunol 170 (2003), 1939–1948.
82. [82] Jiao, X., Lo-Man, R., Guermonprez, P., Fiette, L., Dériaud, E., Burgaud, S., et al. Dendritic cells are host cells for mycobacteria in vivo that trigger innate and acquired immunity. J Immunol 168 (2002), 1294–1301.
83. [83] Förtsch, D., Röllinghoff, M., Stenger, S., IL-10 converts human dendritic cells into macrophage-like cells with increased antibacterial activity against virulent Mycobacterium tuberculosis. J Immunol 165 (2000), 978–987.
84. [84] Martineau, A.R., Newton, S.M., Wilkinson, K.A., Kampmann, B., Hall, B.M., Nawroly, N., et al. Neutrophil-mediated innate immune resistance to mycobacteria. J Clin Invest 117 (2007), 1988–1994.
85. [85] Lowe, D.M., Redford, P.S., Wilkinson, R.J., O'Garra, A., Martineau, A.R., Neutrophils in tuberculosis: friend or foe?. Trends Immunol 33 (2012), 14–25.
86. [86] Junqueira-Kipnis, A.P., Kipnis, A., Jamieson, A., Juarrero, M.G., Diefenbach, A., Raulet, D.H., et al. NK cells respond to pulmonary infection with Mycobacterium tuberculosis, but play a minimal role in protection. J Immunol 171 (2003), 6039–6045.
87. [87] Vankayalapati, R., Wizel, B., Weis, S.E., Safi, H., Lakey, D.L., Mandelboim, O., et al. The NKp46 receptor contributes to NK cell lysis of mononuclear phagocytes infected with an intracellular bacterium. J Immunol 168 (2002), 3451–3457.
88. [88] Vankayalapati, R., Klucar, P., Wizel, B., Weis, S.E., Samten, B., Safi, H., et al. NK cells regulate CD8+ T cell effector function in response to an intracellular pathogen. J Immunol 172 (2004), 130–137.
89. [89] Vankayalapati, R., Garg, A., Porgador, A., Griffith, D.E., Klucar, P., Safi, H., et al. Role of NK cell-activating receptors and their ligands in the lysis of mononuclear phagocytes infected with an intracellular bacterium. J Immunol 175 (2005), 4611–4617.
90. [90] Zhang, R., Zheng, X., Li, B., Wei, H., Tian, Z., Human NK cells positively regulate gammadelta T cells in response to Mycobacterium tuberculosis. J Immunol 176 (2006), 2610–2616.
91. [91] Brill, K.J., Li, Q., Larkin, R., Canaday, D.H., Kaplan, D.R., Boom, W.H., et al. Human natural killer cells mediate killing of intracellular Mycobacterium tuberculosis H37Rv via granule-independent mechanisms. Infect Immun 69 (2001), 1755–1765.
92. [92] Gold, M.C., Napier, R.J., Lewinsohn, D.M., MR1-restricted mucosal associated invariant T (MAIT) cells in the immune response to Mycobacterium tuberculosis. Immunol Rev 264 (2015), 154–166.
93. [93] Montamat-Sicotte, D.J., Millington, K.A., Willcox, C.R., Hingley-Wilson, S., Hackforth, S., Innes, J., et al. A mycolic acid-specific CD1-restricted T cell population contributes to acute and memory immune responses in human tuberculosis infection. J Clin Invest 121 (2011), 2493–2503.
94. [94] Olsen, A.W., Brandt, L., Agger, E.M., van Pinxteren, L.A., Andersen, P., The influence of remaining live BCG organisms in vaccinated mice on the maintenance of immunity to tuberculosis. Scand J Immunol 60 (2004), 273–277.
95. [95] Roy, S., Sharma, S., Sharma, M., Bose, M., Differential signaling of inducible nitric oxide synthase induction in Mycobacterium tuberculosis infected alveolar epithelial cell line A549 in response to cytokines IFN-γ, TNF-α and IL-1β. Int J Mycobacteriol 3 (2014), 17–24.
96. 2 vaccine immunogenicity. ALTEX 31 (2014), 397–406.
97. [97] Duncan, C.J., Hill, A.V., Ellis, R.D., Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?. Hum Vaccin Immunother 8 (2012), 706–714.
98. [98] Naarding, M.A., Fernandez, N., Kappes, J.C., Hayes, P., Ahmed, T., Icyuz, M., et al. Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T-cell responses. J Immunol Methods 409 (2014), 161–173.
99. [99] Bash, M.C., Lynn, F., Mocca, B., Borrow, R., Findlow, H., Hassan-King, M., et al. Development and use of a serum bactericidal assay using pooled human complement to assess responses to a meningococcal group A conjugate vaccine in African toddlers. Clin Vaccine Immunol 21 (2014), 755–761.